Pancreatitis, pancreatic, and thyroid cancer with Glucagon-like peptide-1based therapies

Michael Elashoff, Aleksey V Matveyenko, Belinda Gier, Robert Elashoff, Peter C. Butler

Research output: Contribution to journalArticle

545 Citations (Scopus)

Abstract

Background & Aims: Glucagon-like peptide-1-based therapy is gaining widespread use for type 2 diabetes, although there are concerns about risks for pancreatitis and pancreatic and thyroid cancers. There are also concerns that dipeptidyl peptidase-4 inhibitors could cause cancer, given their effects on immune function. Methods: We examined the US Food and Drug Administration's database of reported adverse events for those associated with the dipeptidyl peptidase-4 inhibitor sitagliptin and the glucagon-like peptide-1 mimetic exenatide, from 2004-2009; data on adverse events associated with 4 other medications were compared as controls. The primary outcomes measures were rates of reported pancreatitis, pancreatic and thyroid cancer, and all cancers associated with sitagliptin or exenatide, compared with other therapies. Results: Use of sitagliptin or exenatide increased the odds ratio for reported pancreatitis 6-fold as compared with other therapies (P < 2 × 10 -16). Pancreatic cancer was more commonly reported among patients who took sitagliptin or exenatide as compared with other therapies (P <.008, P < 9 × 10 -5). All other cancers occurred similarly among patients who took sitagliptin compared with other therapies (P =.20). Conclusions: These data are consistent with case reports and animal studies indicating an increased risk for pancreatitis with glucagon-like peptide-1-based therapy. The findings also raise caution about the potential long-term actions of these drugs to promote pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)150-156
Number of pages7
JournalGastroenterology
Volume141
Issue number1
DOIs
StatePublished - Jul 2011
Externally publishedYes

Fingerprint

Glucagon-Like Peptides
Pancreatic Neoplasms
Thyroid Neoplasms
Pancreatitis
Glucagon-Like Peptide 1
Dipeptidyl-Peptidase IV Inhibitors
Therapeutics
Pharmaceutical Databases
Neoplasms
Type 2 Diabetes Mellitus
Odds Ratio
Outcome Assessment (Health Care)
Sitagliptin Phosphate
Food
exenatide
Pharmaceutical Preparations

Keywords

  • Pancreas
  • Side Effect
  • Toxicity
  • Tumor

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Pancreatitis, pancreatic, and thyroid cancer with Glucagon-like peptide-1based therapies. / Elashoff, Michael; Matveyenko, Aleksey V; Gier, Belinda; Elashoff, Robert; Butler, Peter C.

In: Gastroenterology, Vol. 141, No. 1, 07.2011, p. 150-156.

Research output: Contribution to journalArticle

Elashoff, Michael ; Matveyenko, Aleksey V ; Gier, Belinda ; Elashoff, Robert ; Butler, Peter C. / Pancreatitis, pancreatic, and thyroid cancer with Glucagon-like peptide-1based therapies. In: Gastroenterology. 2011 ; Vol. 141, No. 1. pp. 150-156.
@article{d9f7d45e5ab54c6db05e2b3986911093,
title = "Pancreatitis, pancreatic, and thyroid cancer with Glucagon-like peptide-1based therapies",
abstract = "Background & Aims: Glucagon-like peptide-1-based therapy is gaining widespread use for type 2 diabetes, although there are concerns about risks for pancreatitis and pancreatic and thyroid cancers. There are also concerns that dipeptidyl peptidase-4 inhibitors could cause cancer, given their effects on immune function. Methods: We examined the US Food and Drug Administration's database of reported adverse events for those associated with the dipeptidyl peptidase-4 inhibitor sitagliptin and the glucagon-like peptide-1 mimetic exenatide, from 2004-2009; data on adverse events associated with 4 other medications were compared as controls. The primary outcomes measures were rates of reported pancreatitis, pancreatic and thyroid cancer, and all cancers associated with sitagliptin or exenatide, compared with other therapies. Results: Use of sitagliptin or exenatide increased the odds ratio for reported pancreatitis 6-fold as compared with other therapies (P < 2 × 10 -16). Pancreatic cancer was more commonly reported among patients who took sitagliptin or exenatide as compared with other therapies (P <.008, P < 9 × 10 -5). All other cancers occurred similarly among patients who took sitagliptin compared with other therapies (P =.20). Conclusions: These data are consistent with case reports and animal studies indicating an increased risk for pancreatitis with glucagon-like peptide-1-based therapy. The findings also raise caution about the potential long-term actions of these drugs to promote pancreatic cancer.",
keywords = "Pancreas, Side Effect, Toxicity, Tumor",
author = "Michael Elashoff and Matveyenko, {Aleksey V} and Belinda Gier and Robert Elashoff and Butler, {Peter C.}",
year = "2011",
month = "7",
doi = "10.1053/j.gastro.2011.02.018",
language = "English (US)",
volume = "141",
pages = "150--156",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Pancreatitis, pancreatic, and thyroid cancer with Glucagon-like peptide-1based therapies

AU - Elashoff, Michael

AU - Matveyenko, Aleksey V

AU - Gier, Belinda

AU - Elashoff, Robert

AU - Butler, Peter C.

PY - 2011/7

Y1 - 2011/7

N2 - Background & Aims: Glucagon-like peptide-1-based therapy is gaining widespread use for type 2 diabetes, although there are concerns about risks for pancreatitis and pancreatic and thyroid cancers. There are also concerns that dipeptidyl peptidase-4 inhibitors could cause cancer, given their effects on immune function. Methods: We examined the US Food and Drug Administration's database of reported adverse events for those associated with the dipeptidyl peptidase-4 inhibitor sitagliptin and the glucagon-like peptide-1 mimetic exenatide, from 2004-2009; data on adverse events associated with 4 other medications were compared as controls. The primary outcomes measures were rates of reported pancreatitis, pancreatic and thyroid cancer, and all cancers associated with sitagliptin or exenatide, compared with other therapies. Results: Use of sitagliptin or exenatide increased the odds ratio for reported pancreatitis 6-fold as compared with other therapies (P < 2 × 10 -16). Pancreatic cancer was more commonly reported among patients who took sitagliptin or exenatide as compared with other therapies (P <.008, P < 9 × 10 -5). All other cancers occurred similarly among patients who took sitagliptin compared with other therapies (P =.20). Conclusions: These data are consistent with case reports and animal studies indicating an increased risk for pancreatitis with glucagon-like peptide-1-based therapy. The findings also raise caution about the potential long-term actions of these drugs to promote pancreatic cancer.

AB - Background & Aims: Glucagon-like peptide-1-based therapy is gaining widespread use for type 2 diabetes, although there are concerns about risks for pancreatitis and pancreatic and thyroid cancers. There are also concerns that dipeptidyl peptidase-4 inhibitors could cause cancer, given their effects on immune function. Methods: We examined the US Food and Drug Administration's database of reported adverse events for those associated with the dipeptidyl peptidase-4 inhibitor sitagliptin and the glucagon-like peptide-1 mimetic exenatide, from 2004-2009; data on adverse events associated with 4 other medications were compared as controls. The primary outcomes measures were rates of reported pancreatitis, pancreatic and thyroid cancer, and all cancers associated with sitagliptin or exenatide, compared with other therapies. Results: Use of sitagliptin or exenatide increased the odds ratio for reported pancreatitis 6-fold as compared with other therapies (P < 2 × 10 -16). Pancreatic cancer was more commonly reported among patients who took sitagliptin or exenatide as compared with other therapies (P <.008, P < 9 × 10 -5). All other cancers occurred similarly among patients who took sitagliptin compared with other therapies (P =.20). Conclusions: These data are consistent with case reports and animal studies indicating an increased risk for pancreatitis with glucagon-like peptide-1-based therapy. The findings also raise caution about the potential long-term actions of these drugs to promote pancreatic cancer.

KW - Pancreas

KW - Side Effect

KW - Toxicity

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=79959559653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959559653&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2011.02.018

DO - 10.1053/j.gastro.2011.02.018

M3 - Article

C2 - 21334333

AN - SCOPUS:79959559653

VL - 141

SP - 150

EP - 156

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 1

ER -